| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-12-10 | MGD011 | B-cell hematological malignancies |
preclinical | Macrogenics (USA - MD) | Cancer - Oncology |
| 2014-12-10 | Elecsys® preeclampsia test | preeclampsia |
Roche (Switzerland) | Women health | |
| 2014-12-10 | HDAC6 inhibitors | chronic lymphocytic leukemia |
Kancera (Sweden) | Cancer - Oncology | |
| 2014-12-10 | brexpiprazole (OPC-34712) | patients with major depressive disorder (MDD) who had an inadequate response to monotherapy antidepressant treatments (ADT) |
3 | Lundbeck (Denmark) Otsuka Pharmaceutical (Japan) | CNS diseases - Mental diseases |
| 2014-12-10 | E2006 | insomnia disorder |
2 | Eisai (Japan) | CNS diseases |
| 2014-12-09 | AFFITOPE® PD03A | Parkinson\'s disease |
1 | EU-consortium SYMPATH (AFFiRiS AG (Austria), Biolution GmbH (Austria), University Hospital Bordeaux (France), INSERM F-CRIN Toulouse (France), Prosenex Ambulatorium Betriebs-GmbH (Austria), Medical University Innsbruck, Department of Neurology (Austria), Forschungszentrum Jülich GmbH (Germany),University Hospital Toulouse (France) ) | Neurodegenerative diseases |
| 2014-12-09 | pacritinib | acute myeloid leukemia | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) | Cancer - Oncology | |
| 2014-12-09 | Iclusig® (ponatinib) | heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) |
1 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2014-12-09 | Iclusig® (ponatinib) | 1,2 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology | |
| 2014-12-09 | AN363 | neuropathic pain |
1 | Saniona (Denmark) | CNS diseases |
| 2014-12-09 | lirilumab (BMS-986015) and elotuzumab (BMS-901608) | multiple myeloma |
preclinical | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
| 2014-12-09 | Istodax® (romidepsin) combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) | peripheral t-cell lymphoma |
1,2 | Celgene (USA - NJ) | Cancer - Oncology |
| 2014-12-09 | Mylotarg® (gemtuzumab ozogamicin) | previously untreated patients with acute myeloid leukemia | 3 | Pfizer (USA - NY) | Cancer - Oncology |
| 2014-12-09 | Bosulif® (bosutinib) | chronic myeloid leukemia |
1-2 | Pfizer (USA - NY) | Cancer - Oncology |
| 2014-12-09 | inotuzumab ozogamicin | acute lymphoblastic leukemia (ALL) | 2 | Pfizer (USA - NY) | Cancer - Oncology |
| 2014-12-08 | Zydelig® (idelalisib) | chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL) | 2 | Gilead (USA - CA) | Cancer - Oncology |
| 2014-12-08 | AFM13 | advanced relapsing/refractory Hodgkin lymphoma | 1 | Affimed Therapeutics (Germany) | Cancer - Oncology |
| 2014-12-08 | Tasigna® (nilotinib) | Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase |
3 | Novartis (Switzerland) | Cancer - Oncology |
| 2014-12-08 | JCAR015 - autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor) | acute lymphoblastic leukemia | 1 | Juno Therapeutics (USA - WA) | Cancer - Oncology |
| 2014-12-08 | JCAR015 | non-Hodgkin’s lymphoma (NHL) | 1 | Juno Therapeutics (USA - WA) | Cancer - Oncology |
